Ipsen Appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North America

PARIS–(BUSINESS WIRE)–Regulatory News:

Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment of
Richard Paulson as Executive Vice-President and Chief Executive Officer
of Ipsen North America, responsible for all commercial operations
throughout the region. Mr Paulson will assume oversight of all areas
supporting the North American business effective from February 5th. The
role reports directly to David Meek, CEO of Ipsen, and Mr Paulson will
be a member of the Ipsen Executive Leadership Team. He joins Ipsen from
Amgen where he most recently served as Vice-President and General
Manager of the Oncology Business Unit.

David Meek, Ipsen’s CEO, commented, “We are extremely
delighted to welcome Richard to Ipsen, to drive the continued growth of
our North American business and further our development as a leading
biopharma company focused on innovation and specialty care. Richard
brings a wealth of great leadership experience, vision, and a track
record of exceptional execution in leading and growing businesses, both
in the US and internationally. He will bring great passion and energy to
our work with patients.”

During a 10-year career at Amgen, Richard Paulson held a number of
positions in the company, including General Manager, Central and Eastern
Europe, and subsequently General Manager Germany, before assuming
leadership positions in Amgen’s Oncology Business Unit. Prior to joining
Amgen, he held international positions in general management, marketing
and market access with Pfizer. He also served in a number of sales and
marketing roles with increasing seniority for GlaxoWellcome in Canada.
He holds an MBA from the University of Toronto.

Richard Paulson added: “I am honored to join Ipsen at this
time of rapid transformation and growth, as the company progresses in
its evolution as a leading global biopharma company. Throughout my
career, in markets around the world, I have been passionate about
building and leading diverse, high-performing teams, and driving
innovation for patients. I am extremely excited to join this dynamic
company, with its clear mission and commitment to developing
patient-focused solutions that put the patients’ needs first.”

With the former President North America Cynthia Schwalm leaving Ipsen to
pursue other interests, Ipsen would like to thank Cynthia for her many
contributions to the growth of Ipsen’s North American business, and
wishes her well in her future endeavors.

About Ipsen
Ipsen is a global specialty-driven
biopharmaceutical group focused on innovation and specialty care. The
group develops and commercializes innovative medicines in three key
therapeutic areas – Oncology, Neurosciences and Rare Diseases. Its
commitment to oncology is exemplified through its growing portfolio of
key therapies for prostate cancer, neuroendocrine tumors, renal cell
carcinoma and pancreatic cancer. Ipsen also has a well-established
Consumer Healthcare business. With total sales close to €1.6 billion in
2016, Ipsen sells more than 20 drugs in over 115 countries, with a
direct commercial presence in more than 30 countries. Ipsen’s R&D is
focused on its innovative and differentiated technological platforms
located in the heart of the leading biotechnological and life sciences
hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has
about 5,100 employees worldwide. Ipsen is listed in Paris (Euronext:
IPN) and in the United States through a Sponsored Level I American
Depositary Receipt program (ADR: IPSEY). For more information on Ipsen,
visit www.ipsen.com.

Ipsen Forward Looking Statement
The forward-looking
statements, objectives and targets contained herein are based on the
Group’s management strategy, current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may
cause actual results, performance or events to differ materially from
those anticipated herein. All of the above risks could affect the
Group’s future ability to achieve its financial targets, which were set
assuming reasonable macroeconomic conditions based on the information
available today. Use of the words “believes,” “anticipates” and
“expects” and similar expressions are intended to identify
forward-looking statements, including the Group’s expectations regarding
future events, including regulatory filings and determinations.
Moreover, the targets described in this document were prepared without
taking into account external growth assumptions and potential future
acquisitions, which may alter these parameters. These objectives are
based on data and assumptions regarded as reasonable by the Group. These
targets depend on conditions or facts likely to happen in the future,
and not exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain risks
and uncertainties, notably the fact that a promising product in early
development phase or clinical trial may end up never being launched on
the market or reaching its commercial targets, notably for regulatory or
competition reasons. The Group must face or might face competition from
generic products that might translate into a loss of market share.
Furthermore, the Research and Development process involves several
stages each of which involves the substantial risk that the Group may
fail to achieve its objectives and be forced to abandon its efforts with
regards to a product in which it has invested significant sums.
Therefore, the Group cannot be certain that favourable results obtained
during pre-clinical trials will be confirmed subsequently during
clinical trials, or that the results of clinical trials will be
sufficient to demonstrate the safe and effective nature of the product
concerned. There can be no guarantees a product will receive the
necessary regulatory approvals or that the product will prove to be
commercially successful. If underlying assumptions prove inaccurate or
risks or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Other risks and
uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation; global
trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new
product development, including obtaining regulatory approval; the
Group’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the
effectiveness of the Group’s patents and other protections for
innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions. The Group also depends on third
parties to develop and market some of its products which could
potentially generate substantial royalties; these partners could behave
in such ways which could cause damage to the Group’s activities and
financial results. The Group cannot be certain that its partners will
fulfil their obligations. It might be unable to obtain any benefit from
those agreements. A default by any of the Group’s partners could
generate lower revenues than expected. Such situations could have a
negative impact on the Group’s business, financial position or
performance. The Group expressly disclaims any obligation or undertaking
to update or revise any forward-looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such statements
are based, unless so required by applicable law. The Group’s business is
subject to the risk factors outlined in its registration documents filed
with the French Autorité des Marchés Financiers.
The risks and
uncertainties set out are not exhaustive and the reader is advised to
refer to the Group’s 2016 Registration Document available on its website


Ian Weatherhead
Corporate External Communications
Tel.: +44 (0)7584 230549
Vice-President, North American Internal & External
Tel: +1 908 275 6330
Email: marisol.peron@ipsen.com
Le Guennec
Senior Manager, Corporate External Communications
+33 (0)1 58 33 51 17
E-mail: brigitte.le.guennec@ipsen.com